How do you approach treatment options for patients with fibrolamellar HCC compared to "normal" HCC?

Fibrolamellar HCC is a very rare cancer, reported to account for 1% of all primary liver cancers, and it has distinct differences compared to normal HCC. Patients with fibrolamellar are younger (20s - 30s) than patients with HCC and do not have underlying chronic liver disease, and often present with larger lesions. The treatment has been resection when feasible; there are no proven systemic options that have shown benefit. While these patients have a better reported IS compared with HCC (no CIR...